I'm LongbridgeAI, I can summarize articles.Positive topline results from the STENOVA OLE study show ontunisertib maintained a favorable safety profile and sustained disease control in FSCD patients over 60 weeks, with a low 3% annualized event rate and no surgeries. These findings support advancing to a global Phase 2b trial.Original document: AgomAb Therapeutics NV [AGMB] Press release — Oct. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Positive topline results from the STENOVA OLE study show ontunisertib maintained a favorable safety profile and sustained disease control in FSCD patients over 60 weeks, with a low 3% annualized event rate and no surgeries. These findings support advancing to a global Phase 2b trial.
Original document: AgomAb Therapeutics NV [AGMB] Press release — Oct. 1 2026